MedTrace Logo

A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy

NCT06075043 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-02-27

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of various doses of AND017 after 6 weeks of treatment in subjects with anemia of cancer who are not receiving chemotherapy.

Conditions

  • Cancer-Related Anemia

Interventions

DRUG

AND017

Oral administration of AND017 capsules three times per week

Sponsors & Collaborators

  • Kind Pharmaceuticals LLC

    lead INDUSTRY

Principal Investigators

  • Yusha Zhu, MD, PhD · Kind Pharmaceuticals LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-12-31
Primary Completion
2028-05-31
Completion
2028-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06075043 on ClinicalTrials.gov